Monte Rosa reports Q3 net loss $27.1M; second Novartis deal with $120M upfront

Monte Rosa Therapeutics, Inc.

Net loss $27.1M vs $23.9M YoY; collaboration revenue $12.8M (vs $9.2M).
Second Novartis agreement: $120M upfront, total eligible up to $5.7B for immune-mediated disease degraders.
Phase 1 NEK7 MGD MRT-8102 enrolling; initial data including high-CVD risk cohort on track for H1 2026.
Cash $396.2M at Sept. 30; raised $23.9M net from October ATM; runway through 2028.
MRT-2359 mCRPC data by year-end; CDK2/cyclin E1 IND submission targeted for 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.